malaria vaccine R21 Matrix-M
Selected indexed studies
- Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. (Lancet, 2024) [PMID:38310910]
- A perspective on Oxford's R21/Matrix-M™ malaria vaccine and the future of global eradication efforts. (Malar J, 2024) [PMID:38216923]
- R21/Matrix-M: a second malaria vaccine? (Lancet, 2021) [PMID:33964224]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. (2024) pubmed
- A perspective on Oxford's R21/Matrix-M™ malaria vaccine and the future of global eradication efforts. (2024) pubmed
- R21/Matrix-M: a second malaria vaccine? (2021) pubmed
- Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context. (2025) pubmed
- Hesitancy towards R21/Matrix-M malaria vaccine among Ghanaian parents and attitudes towards immunizing non-eligible children: a cross-sectional survey. (2024) pubmed
- R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial. (2025) pubmed
- R21/Matrix-M vaccine: optimising supply, maximising impact. (2024) pubmed
- Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine. (2025) pubmed
- Vaccine-induced responses to R21/Matrix-M - an analysis of samples from a phase 1b age de-escalation, dose-escalation trial. (2025) pubmed
- R21/Matrix-M™ malaria vaccine: a new tool to achieve WHO's goal to eliminate malaria in 30 countries by 2030? (2023) pubmed